Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray.
OBJECTIVE
The objective of this study was to screen and identify differentially expressed genes in invasive bladder transitional cell carcinoma (BTCC).


METHODS
Voided urine samples were collected from consecutive patients with BTCC and patients under surveillance for bladder cancer recurrence; voided urine samples from patients with non-malignant diseases served as control. We identified the differentially expressed genes by comparing urine samples of bladder carcinoma to that of the control group with suppressive subtractive hybridization (SSH) and cDNA microarray. The differentially expressed genes were verified by quantitative real-time polymerase chain reaction (QPCR).


RESULTS
From the 762 white colonies, a total of 449 positive clones were obtained in which 112 were found to be upregulated in BTCC. Sequencing and homology analysis were performed for these 112 clonies. The detection rates of some known genes (including IGF-1, human telomerase reverse transcriptase [hTERT], bladder cancer specific nuclear matrix protein 4 [BLCA-4] and homeobox A13 [HOXA13]) for BTCC at the Ta, T1 and >T1 stages were 48%, 90% and 100%, respectively, with a specificity of 85%. The test specificity was 80% for the 30 control patients with urinary tract infections. The combination of BLCA-4 and HOXA13 could distinguish between low- and high-grade tumours, with specificity and sensitivity of 80%.


CONCLUSIONS
We successfully constructed a reliable SSH library of BTCC and found that combination detection insulin-like growth factor 1 (IGF-1), hTERT, BLCA-4 and HOXA13 genes could help to evaluate BTCC at different stages.
The First Affiliated Hospital of Lanzhou University, Lanzhou, China;
Baihong
B
Guo
Tuanjie
T
Che
Baoguang
B
Shi
Lijun
L
Guo
Yongsheng
Y
Yin
Lin
L
Li
Jinming
J
Wang
Dongwen
D
Yan
Yirong
Y
Chen
Int J Antimicrob Agents. 2004 Jan;23(1):72-9
14732317
Plant Cell Rep. 2004 Nov;23(5):263-71
15368076
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Clin Cancer Res. 2005 Jun 1;11(11):4044-55
15930339
Eur Urol. 2001 Jun;39(6):619-33
11464050
Cancer Lett. 2007 Apr 28;249(1):97-109
17287077
Urol Res. 2003 Oct;31(5):297-9
14574532
Clin Cancer Res. 2005 Jun 15;11(12):4415-29
15958626
J Urol. 2002 Jun;167(6):2404-7
11992046
Urology. 1998 Nov;52(5):793-6
9801101
Clin Cancer Res. 2004 Feb 15;10(4):1384-91
14977841
Proc Natl Acad Sci U S A. 1988 Jan;85(1):121-5
3277168
Nat Genet. 2003 Jan;33(1):90-6
12469123
J Biochem. 2005 Jun;137(6):671-6
16002988
Am J Clin Pathol. 2001 Jul;116(1):79-86
11447756
Nat Protoc. 2008;3(6):1101-8
18546601
J Clin Oncol. 2006 Feb 10;24(5):778-89
16432078
Ann Clin Biochem. 2007 Nov;44(Pt 6):523-8
17961306
Urology. 2005 Dec;66(6):1256-60
16360453
Clin Chem. 1999 Apr;45(4):472-7
10102906
J Mol Diagn. 2009 Mar;11(2):148-54
19179455
Anal Biochem. 2002 Jan 15;300(2):269-73
11779121
Clin Cancer Res. 2005 Jun 1;11(11):4029-36
15930337